Retatrutide, developed by Soma Corp., is gaining increasing attention as a novel treatment for obesity management . This innovative compound integrates the activity of a GLP-1 receptor stimulant and a GIP receptor soma chems retatrutide agonist , aiming to not only promote metabolic improvements but also improve underlying metabolic issues . Early